Dealing with atopic dermatitis with Dr. Ashley Bourgeois | VETgirl Veterinary Continuing Education Podcasts
In this VETgirl online veterinary CE podcast, we interview Dr. Ashley Bourgeois, DACVD, the “Derm Vet,” on all things atopic dermatitis related. Dr. Bourgeois practices as a board-certified dermatologist at Animal Dermatology Clinic inPortland, OR. Here, she’ll discuss how you can “ditch the itch” and get your veterinary practice ready for Itchy Pet Awareness Month in August. Learn how to better communicate with your derm clients and set expectations on management and treatment of this life-long disease!
Today’s VETgirl podcast was sponsored by Zoetis, the makers of treatments including APOQUEL (oclacitinib tablet) and CYTOPONT. Zoetis is dedicated to changing the way we approach canine pruritus to protect the bonds between the pet, the owner and the veterinary team. Visit ScienceofStrongerBonds.com for more information.
Important Safety Information
Do not use APOQUEL in dogs less than 12 months of age or those with serious infections. APOQUEL may increase the chances of developing serious infections, and may cause existing parasitic skin infestations or pre-existing cancers to get worse. Consider the risks and benefits of treatment in dogs with a history of recurrence of these conditions. New neoplastic conditions (benign and malignant) were observed in clinical studies and post-approval. APOQUEL has not been tested in dogs receiving some medications including some commonly used to treat skin conditions such as corticosteroids and cyclosporines. Do not use in breeding, pregnant, or lactating dogs. Most common side effects are vomiting and diarrhea. APOQUEL has been used safely with many common medications including parasiticides, antibiotics and vaccines. For more information, please see the full Prescribing Information at APOQUEL.com.
Control of pruritus (itching) associated with allergic dermatitis and control of atopic dermatitis in dogs at least 12 months of age.
CYTOPOINT® Indications: CYTOPOINT has been shown to be effective for the treatment of dogs against allergic dermatitis and atopic dermatitis.
Zoetis is dedicated to changing the way we approach canine pruritus to protect the bonds between the pet, the owner and the veterinary team. Visit ScienceofStrongerBonds.com for more information.
1. Olivry et al. Treatment of canine atopic dermatitis: 2015 updated guidelines from the international committee on allergic diseases of animals (ICADA). BMC Veterinary Research 2015;11:210. AR-02860
2. Gadeyne, Little, King, et al. Efficacy of oclacitinib (APOQUEL®) compared with prednisolone for the control of pruritus and clinical signs associated with allergic dermatitis in client‐owned dogs in Australia. Vet Dermatol 2014;25(6):512–e86. AR-01594
3. Gonzales AJ, Bowman JW, Fici GJ, et al. Oclacitinib (APOQUEL®) is a novel Janus kinase inhibitor with activity against cytokines involved in allergy. J Vet Pharmacol Ther. 2014;37(4):317–324. AR-00797
4. Data on file, Study Report No. C961R-US-13-051, Zoetis LLC. TI-01245